Moustafa Abdou: Ehlers-Danlos Syndrome – Why Collagen Matters for Hemostasis
Moustafa Abdou, Author and Founder of AskHematologist.com, shared a post on LinkedIn:
“Ehlers-Danlos Syndrome (EDS)
Normal lab results don’t always mean normal hemostasis.
When a patient presents with extensive bruising but their platelet count and coagulation screens are completely normal, the culprit is often structural, not circulating.
In Ehlers-Danlos Syndrome (EDS), easy bruising occurs due to increased fragility of dermal blood capillaries and poor structural integrity of the skin, rather than a clotting abnormality.
Mutations affecting collagen synthesis or its modifying enzymes leave blood vessel walls without their vital connective tissue support.
While classic and hypermobility types cause troublesome capillary bleeding, recognizing the rarer types—like Vascular EDS—is critical, as tissue weakness can lead to life-threatening arterial or organ rupture.
A solid grasp of vascular bleeding disorders prevents unnecessary hematologic testing and ensures appropriate clinical management.
Read the Full Clinical Breakdown.”
Other posts featuring Moustafa Abdou on Hemostasis Today.
-
Nov 13, 2026, 16:17Shailendra Singh: Bombay Hospital Jaipur Inaugurates New Facility with Voluntary Blood Donation Camp
-
Nov 13, 2026, 16:10Minka Zivkovic: UMC Utrecht Announces Research Analyst Vacancy in Thrombosis and Haemostasis
-
Nov 13, 2026, 16:02Rounak Dubey: Elsevier’s Upcoming Handbook Explores Digitalization in Transfusion Medicine
-
Nov 13, 2026, 15:50Maha Othman: CanVECTOR 2026 Highlights Research on Immunothrombosis and Cancer-Associated Thrombosis
-
Nov 13, 2026, 15:48Cedric Hermans: Advances in Gene Therapy for Haemophilia A
-
Nov 13, 2026, 15:45Strengthens Global Collaboration in Thrombosis and Hemostasis for 2027 – ISTH
-
Nov 13, 2026, 15:42David McIntosh: The Global Blood Shortage Crisis and the Urgent Need for National Action
-
Nov 13, 2026, 15:41JTH Highlights Future Directions in Thromboprophylaxis for Hospitalized Children
-
Nov 13, 2026, 15:21Wolfgang Miesbach։ Gene Therapy for Haemophilia B Is Cheaper Than Lifelong Factor IX Prophylaxis in Sweden